Search results
Results from the WOW.Com Content Network
Since lupus nephritis is a serious, disabling, and possibly life-threatening illness, it is not surprising to see mortality in lupus nephritis clinical trials. Voclosporin safety information originates from a total of 267 patients who received 23.7 mg BID and an additional 88 patients who received 39.5 mg BID.
The Phase 3 trial would be initiated after agreement with the FDA on a pivotal trial design. CB-010, a clinical-stage allogeneic anti-CD19 CAR-T cell therapy for lupus. Caribou expanded the CB-010 program following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for CB-010 in LN and ERL.
Ianalumab (INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjogren's disease, and systemic lupus erythematosus. [2] [3] [4] This drug is being developed by Novartis. In 2021 ianalumab was undergoing Phase II/III trials.
Belimumab was not effective in Phase II clinical trials for rheumatoid arthritis. [30] It was moderately effective in Phase II trials for Sjögren syndrome. [31] In December 2020, belimumab was approved by the FDA as a treatment for lupus nephritis in combination with standard treatment. [32]
The proliferative forms of lupus nephritis are associated with a higher risk of progression to end stage kidney disease. [21] Black and Hispanic people with lupus nephritis are more likely to present with severe disease at initial presentation (with more proteinuria and more extensive histopathologic changes) and progress to end stage kidney ...
The cause of diffuse proliferative glomerulonephritis (DPGN) depends on the severity of the disease. DPGN is a secondary disease, in that a disease that a patient already has causes DPGN to occur. The most common associated disease of DPGN is severe systemic lupus erythematosus(SLE). [4] Specifically, Lupus nephritis class IV. [5]
Lupus nephritis: Kidneys: Anti-dsDNA, Anti-Sm, Anti-nuclear antibodies Confirmed Up to 60% of those with Lupus [49] Interstitial nephritis: Kidneys: Various autoantibodies Probable Varies widely, often drug-induced [50] Interstitial cystitis: Bladder: Anti-urothelial and anti-nuclear antibodies Probable 100-450 per 100,000 women, less common in ...
Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug ...